Global Branded Generics Market: By Disease Indication (Cardiovascular Diseases, Diabetes, Cancer, Neurological Disorders, Gastrointestinal Diseases, Dermatology Diseases, and Others), By Route of Administration (Oral, Parenteral, Topical, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies), and Geography - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Global Branded Generics Market Report Description:
Branded generics market report gives comprehensive outlook on branded generics across the globe with special emphasis on key regions such as Asia-Pacific, Latin America, Middle East & Africa (MEA), North America, and Europe. Branded generics market report deals with deals with detailed market outlook in Emerging markets such as Brazil, Russia, China, India, and other Eastern Europe, Latin American countries. The report on branded generics market gives historical, current, and future market sizes (US$ Mn) on the basis of diseases Indication, route of administration, distribution channel, and geographic regions. This report studies branded generics market dynamics in emerging markets and developed markets elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, branded generics market report includes new product introductions, recent drug patent expiration data, regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed branded generics market to better equip clients with possible investment opportunities across the emerging markets (Regional Investment Hot-Spots) and market unmet needs (Product/Disease Opportunities). Key stakeholders of the branded generics market report include suppliers, manufacturers, marketers, policy makers engaged in manufacturing and supply of branded generics.
Branded Generics Market:
The branded generics market estimated to be valued US$ 224.0 Bn in 2017 and poised to grow at CAGR 7.7 %. Market for branded generics projected to reach US$ 350.0 Bn by 2023.
Increasing prevalence of chronic diseases such as diabetes, hypertension coupled with rising out-of pocket healthcare expenditure driving the branded generics market revenue growth in developing regions
Market for branded generics expected to register around double digit growth rate in emerging economies owing to widespread prevalence of lifestyle and chronic diseases like diabetes and cardiovascular diseases. The growing life style changes along with rising disposable income in middle classes are factors expected to prompt the market growth in near future. According to International diabetes Federation (IDF) atlas, 2015 emerging nations like India and China, Brazil and Russia falls under top ten countries for diabetic population.
Rising patent expirations and a lull in developed pharmaceutical market growth
Developed pharmaceutical markets like North America, Europe, and Japan has been witnessing relatively slower market growth in comparing with developing markets owing to fewer new product approvals from the regulatory bodies and bleak late stage pipeline. This has been led to the change in focus by several multinational pharmaceutical giants from matured markets to developing markets to tap ever-growing market opportunities in these regions. Moreover, increasing product patent expirations expected to boost the branded generics revenue growth in developing and mature markets across the globe.
Asia-Pacific accounts for larger market revenue share in global branded generics market
Asia-pacific expected to lead the global branded generics market in terms of revenue in over forecast period owing to higher out-of pocket healthcare expenditure and lack of universal health coverage. Moreover, countries like India, China, and ASEAN countries presented better growth opportunities for the existing and new players in the market. Regions such as Asia Latin America and Eastern Europe projected to grow at significant CAGR over the forecast period
COMPETITION ASSESSMENT
Key players profiles in the global branded generics market include:
KEY FINDINGS OF THE REPORT:
By Diseases Indication
Branded generics market report gives comprehensive outlook on branded generics across the globe with special emphasis on key regions such as Asia-Pacific, Latin America, Middle East & Africa (MEA), North America, and Europe. Branded generics market report deals with deals with detailed market outlook in Emerging markets such as Brazil, Russia, China, India, and other Eastern Europe, Latin American countries. The report on branded generics market gives historical, current, and future market sizes (US$ Mn) on the basis of diseases Indication, route of administration, distribution channel, and geographic regions. This report studies branded generics market dynamics in emerging markets and developed markets elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, branded generics market report includes new product introductions, recent drug patent expiration data, regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed branded generics market to better equip clients with possible investment opportunities across the emerging markets (Regional Investment Hot-Spots) and market unmet needs (Product/Disease Opportunities). Key stakeholders of the branded generics market report include suppliers, manufacturers, marketers, policy makers engaged in manufacturing and supply of branded generics.
Branded Generics Market:
The branded generics market estimated to be valued US$ 224.0 Bn in 2017 and poised to grow at CAGR 7.7 %. Market for branded generics projected to reach US$ 350.0 Bn by 2023.
Increasing prevalence of chronic diseases such as diabetes, hypertension coupled with rising out-of pocket healthcare expenditure driving the branded generics market revenue growth in developing regions
Market for branded generics expected to register around double digit growth rate in emerging economies owing to widespread prevalence of lifestyle and chronic diseases like diabetes and cardiovascular diseases. The growing life style changes along with rising disposable income in middle classes are factors expected to prompt the market growth in near future. According to International diabetes Federation (IDF) atlas, 2015 emerging nations like India and China, Brazil and Russia falls under top ten countries for diabetic population.
Rising patent expirations and a lull in developed pharmaceutical market growth
Developed pharmaceutical markets like North America, Europe, and Japan has been witnessing relatively slower market growth in comparing with developing markets owing to fewer new product approvals from the regulatory bodies and bleak late stage pipeline. This has been led to the change in focus by several multinational pharmaceutical giants from matured markets to developing markets to tap ever-growing market opportunities in these regions. Moreover, increasing product patent expirations expected to boost the branded generics revenue growth in developing and mature markets across the globe.
Asia-Pacific accounts for larger market revenue share in global branded generics market
Asia-pacific expected to lead the global branded generics market in terms of revenue in over forecast period owing to higher out-of pocket healthcare expenditure and lack of universal health coverage. Moreover, countries like India, China, and ASEAN countries presented better growth opportunities for the existing and new players in the market. Regions such as Asia Latin America and Eastern Europe projected to grow at significant CAGR over the forecast period
COMPETITION ASSESSMENT
Key players profiles in the global branded generics market include:
- Abbott Laboratories (U.S.)
- Apotex Inc. (Canada)
- AstraZeneca (U.K)
- Dr. Reddy’s Laboratories Ltd. (India)
- GlaxoSmithKline plc (U.K)
- Mylan N.V. (U.S.)
- Pfizer Inc. (U.S)
- Novartis AG (Switzerland)
- Sanofi (France)
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceutical Industries Ltd (Israel)
- Valeant Pharmaceuticals International, Inc. (Canada)
KEY FINDINGS OF THE REPORT:
- Branded Generics market expanding at 7.7% CAGR over 2017 to 2023 to reach market value of US$ 350.0 Bn by 2023 owing increase in prevalence of chronic and life style disease in emerging markets
- Based on diseases Indication, cardiovascular diseases sub-segment projected to garner larger market revenue share in over forecast period owing to rising co-morbidities like diabetes and cardiovascular diseases
- Hospital and retail pharmacies are prime distribution channels for branded generics across the regions owing to accessibility and availability drugs
- Players focusing on increasing geographic foot-prints to garner growing market opportunities in developing countries
- The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
By Diseases Indication
- Cardiovascular Diseases
- Diabetes
- Cancer
- Neurological Disorders
- Gastrointestinal Diseases
- Dermatology Diseases
- Others
- Oral
- Parenteral
- Topical
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
- North America
- U.S
- Canada
- Europe
- Germany
- France
- U.K
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia & New Zealand
- ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Venezuela
- Rest of Latin America
- Middle East and Africa (MEA)
- Gulf Cooperation Council (GCC) Countries
- Israel
- South Africa
- Rest of MEA
1. RESEARCH METHODOLOGY
1.1. Secondary and Primary research
1.1.1. Secondary Sources
1.1.2. Primary Sources
1.2. Market Revenue Estimation Methodology
1.3. Key Assumptions
1.4. Acronyms
2. SCOPE OF STUDY
2.1. Market Definition
2.2. Objective of the Research
2.3. Regions covered in the study
3. EXECUTIVE SUMMARY
4. GLOBAL BRANDED GENERICS IN MARKET DYNAMICS
4.1. Drivers
4.1.1. Economic Drivers
4.1.2. Demand Side Drivers
4.1.3. Supply Side Drivers
4.2. Restraints
4.3. Opportunities/Unmet Needs of the Market
4.4. Trends
5. UNIQUE FEATURES OF THE REPORT
5.1. Competition analysis
5.2. Regulatory landscape
5.3. PESTLE analysis
5.4. Porter’s analysis
6. GLOBAL BRANDED GENERICS MARKET ANALYSIS, BY DISEASES INDICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Cardiovascular Diseases
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.2. Diabetes
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.3. Cancer
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.4. Neurological Disorders
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.5. Gastrointestinal Diseases
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.6. Dermatology Diseases
6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.7. Others
6.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7. GLOBAL BRANDED GENERICS MARKET ANALYSIS, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Oral
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2. Parenteral
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.3. Topical
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.4. Others
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8. BRANDED GENERICS IN MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.3. Drug Stores
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.4. Online Pharmacies
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9. GLOBAL BRANDED GENERICS MARKET ANALYSIS, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. North America Branded Generics Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.1.1. Diseases Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.1.1.1. Cardiovascular Diseases
9.1.1.2. Diabetes
9.1.1.3. Cancer
9.1.1.4. Neurological Disorders
9.1.1.5. Gastrointestinal Diseases
9.1.1.6. Dermatology Diseases
9.1.1.7. Others
9.1.2. Route of Administration Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.1.2.1. Oral
9.1.2.2. Parenteral
9.1.2.3. Topical
9.1.2.4. Others
9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Online Pharmacies
9.1.3.4. Drug Stores
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.1.4.1. U.S
9.1.4.2. Canada
9.2. Europe Branded Generics Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.2.1. Diseases Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.2.1.1. Cardiovascular Diseases
9.2.1.2. Diabetes
9.2.1.3. Cancer
9.2.1.4. Neurological Disorders
9.2.1.5. Gastrointestinal Diseases
9.2.1.6. Dermatology Diseases
9.2.1.7. Others
9.2.2. Route of Administration Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.2.2.1. Oral
9.2.2.2. Parenteral
9.2.2.3. Topical
9.2.2.4. Others
9.2.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.2.3.1. Hospital Pharmacies
9.2.3.2. Retail Pharmacies
9.2.3.3. Online Pharmacies
9.2.3.4. Drug Stores
9.2.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.2.4.1. Germany
9.2.4.2. France
9.2.4.3. U.K
9.2.4.4. Italy
9.2.4.5. Spain
9.2.4.6. Russia
9.2.4.7. Poland 9.2.4.8. Rest of Europe
9.3. Asia-Pacific Branded Generics Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.3.1. Diseases Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.3.1.1. Cardiovascular Diseases
9.3.1.2. Diabetes
9.3.1.3. Cancer
9.3.1.4. Neurological Disorders
9.3.1.5. Gastrointestinal Diseases
9.3.1.6. Dermatology Diseases
9.3.1.7. Others
9.3.2. Route of Administration Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.3.2.1. Oral
9.3.2.2. Parenteral
9.3.2.3. Topical
9.3.2.4. Others
9.3.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.3.3.1. Hospital Pharmacies
9.3.3.2. Retail Pharmacies
9.3.3.3. Online Pharmacies
9.3.3.4. Drug Stores
9.3.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.3.4.1. Japan
9.3.4.2. China
9.3.4.3. India
9.3.4.4. Australia & New Zealand 9.3.4.5. ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
9.3.4.6. South Korea
9.4. Latin America Branded Generics Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.4.1. Diseases Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.4.1.1. Cardiovascular Diseases
9.4.1.2. Diabetes
9.4.1.3. Cancer
9.4.1.4. Neurological Disorders
9.4.1.5. Gastrointestinal Diseases
9.4.1.6. Dermatology Diseases
9.4.1.7. Others
9.4.2. Route of Administration Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.4.2.1. Oral
9.4.2.2. Parenteral
9.4.2.3. Topical
9.4.2.4. Others
9.4.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.4.3.1. Hospital Pharmacies
9.4.3.2. Retail Pharmacies
9.4.3.3. Online Pharmacies
9.4.3.4. Drug Stores
9.4.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.4.4.1. Brazil
9.4.4.2. Mexico
9.4.4.3. Argentina
9.4.4.4. Venezuela
9.4.4.5. Rest of Latin America
9.5. Middle East & Africa (MEA) Biosimilars Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.5.1. Diseases Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.5.1.1. Cardiovascular Diseases
9.5.1.2. Diabetes
9.5.1.3. Cancer
9.5.1.4. Neurological Disorders
9.5.1.5. Gastrointestinal Diseases
9.5.1.6. Dermatology Diseases
9.5.1.7. Others
9.5.2. Route of Administration Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.5.2.1. Oral
9.5.2.2. Parenteral
9.5.2.3. Topical
9.5.2.4. Others
9.5.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.5.3.1. Hospital Pharmacies
9.5.3.2. Retail Pharmacies
9.5.3.3. Online Pharmacies
9.5.3.4. Drug Stores
9.5.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.5.4.1. Gulf Cooperation Council (GCC) Countries
9.5.4.2. Israel
9.5.4.3. South Africa
9.5.4.4. Rest of MEA
10. COMPETITION LANDSCAPE
10.1. Strategic Dashboard of Top Market Players
10.2. Company Profiles (Introduction, Financial Analysis, Products & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
10.2.1. Abbott Laboratories (U.S.)
10.2.2. Apotex Inc. (Canada)
10.2.3. AstraZeneca (U.K)
10.2.4. Dr. Reddy’s Laboratories Ltd. (India)
10.2.5. GlaxoSmithKline plc (U.K)
10.2.6. Mylan N.V. (U.S.)
10.2.7. Pfizer Inc. (U.S)
10.2.8. Novartis AG (Switzerland)
10.2.9. Sanofi (France)
10.2.10. Sun Pharmaceutical Industries Ltd. (India)
10.2.11. Teva Pharmaceutical Industries Ltd (Israel)
Valeant Pharmaceuticals International, Inc. (Canada)
1.1. Secondary and Primary research
1.1.1. Secondary Sources
1.1.2. Primary Sources
1.2. Market Revenue Estimation Methodology
1.3. Key Assumptions
1.4. Acronyms
2. SCOPE OF STUDY
2.1. Market Definition
2.2. Objective of the Research
2.3. Regions covered in the study
3. EXECUTIVE SUMMARY
4. GLOBAL BRANDED GENERICS IN MARKET DYNAMICS
4.1. Drivers
4.1.1. Economic Drivers
4.1.2. Demand Side Drivers
4.1.3. Supply Side Drivers
4.2. Restraints
4.3. Opportunities/Unmet Needs of the Market
4.4. Trends
5. UNIQUE FEATURES OF THE REPORT
5.1. Competition analysis
5.2. Regulatory landscape
5.3. PESTLE analysis
5.4. Porter’s analysis
6. GLOBAL BRANDED GENERICS MARKET ANALYSIS, BY DISEASES INDICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Cardiovascular Diseases
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.2. Diabetes
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.3. Cancer
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.4. Neurological Disorders
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.5. Gastrointestinal Diseases
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.6. Dermatology Diseases
6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.7. Others
6.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7. GLOBAL BRANDED GENERICS MARKET ANALYSIS, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Oral
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2. Parenteral
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.3. Topical
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.4. Others
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8. BRANDED GENERICS IN MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.3. Drug Stores
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.4. Online Pharmacies
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9. GLOBAL BRANDED GENERICS MARKET ANALYSIS, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. North America Branded Generics Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.1.1. Diseases Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.1.1.1. Cardiovascular Diseases
9.1.1.2. Diabetes
9.1.1.3. Cancer
9.1.1.4. Neurological Disorders
9.1.1.5. Gastrointestinal Diseases
9.1.1.6. Dermatology Diseases
9.1.1.7. Others
9.1.2. Route of Administration Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.1.2.1. Oral
9.1.2.2. Parenteral
9.1.2.3. Topical
9.1.2.4. Others
9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Online Pharmacies
9.1.3.4. Drug Stores
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.1.4.1. U.S
9.1.4.2. Canada
9.2. Europe Branded Generics Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.2.1. Diseases Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.2.1.1. Cardiovascular Diseases
9.2.1.2. Diabetes
9.2.1.3. Cancer
9.2.1.4. Neurological Disorders
9.2.1.5. Gastrointestinal Diseases
9.2.1.6. Dermatology Diseases
9.2.1.7. Others
9.2.2. Route of Administration Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.2.2.1. Oral
9.2.2.2. Parenteral
9.2.2.3. Topical
9.2.2.4. Others
9.2.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.2.3.1. Hospital Pharmacies
9.2.3.2. Retail Pharmacies
9.2.3.3. Online Pharmacies
9.2.3.4. Drug Stores
9.2.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.2.4.1. Germany
9.2.4.2. France
9.2.4.3. U.K
9.2.4.4. Italy
9.2.4.5. Spain
9.2.4.6. Russia
9.2.4.7. Poland 9.2.4.8. Rest of Europe
9.3. Asia-Pacific Branded Generics Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.3.1. Diseases Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.3.1.1. Cardiovascular Diseases
9.3.1.2. Diabetes
9.3.1.3. Cancer
9.3.1.4. Neurological Disorders
9.3.1.5. Gastrointestinal Diseases
9.3.1.6. Dermatology Diseases
9.3.1.7. Others
9.3.2. Route of Administration Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.3.2.1. Oral
9.3.2.2. Parenteral
9.3.2.3. Topical
9.3.2.4. Others
9.3.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.3.3.1. Hospital Pharmacies
9.3.3.2. Retail Pharmacies
9.3.3.3. Online Pharmacies
9.3.3.4. Drug Stores
9.3.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.3.4.1. Japan
9.3.4.2. China
9.3.4.3. India
9.3.4.4. Australia & New Zealand 9.3.4.5. ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
9.3.4.6. South Korea
9.4. Latin America Branded Generics Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.4.1. Diseases Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.4.1.1. Cardiovascular Diseases
9.4.1.2. Diabetes
9.4.1.3. Cancer
9.4.1.4. Neurological Disorders
9.4.1.5. Gastrointestinal Diseases
9.4.1.6. Dermatology Diseases
9.4.1.7. Others
9.4.2. Route of Administration Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.4.2.1. Oral
9.4.2.2. Parenteral
9.4.2.3. Topical
9.4.2.4. Others
9.4.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.4.3.1. Hospital Pharmacies
9.4.3.2. Retail Pharmacies
9.4.3.3. Online Pharmacies
9.4.3.4. Drug Stores
9.4.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.4.4.1. Brazil
9.4.4.2. Mexico
9.4.4.3. Argentina
9.4.4.4. Venezuela
9.4.4.5. Rest of Latin America
9.5. Middle East & Africa (MEA) Biosimilars Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.5.1. Diseases Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.5.1.1. Cardiovascular Diseases
9.5.1.2. Diabetes
9.5.1.3. Cancer
9.5.1.4. Neurological Disorders
9.5.1.5. Gastrointestinal Diseases
9.5.1.6. Dermatology Diseases
9.5.1.7. Others
9.5.2. Route of Administration Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.5.2.1. Oral
9.5.2.2. Parenteral
9.5.2.3. Topical
9.5.2.4. Others
9.5.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.5.3.1. Hospital Pharmacies
9.5.3.2. Retail Pharmacies
9.5.3.3. Online Pharmacies
9.5.3.4. Drug Stores
9.5.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.5.4.1. Gulf Cooperation Council (GCC) Countries
9.5.4.2. Israel
9.5.4.3. South Africa
9.5.4.4. Rest of MEA
10. COMPETITION LANDSCAPE
10.1. Strategic Dashboard of Top Market Players
10.2. Company Profiles (Introduction, Financial Analysis, Products & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
10.2.1. Abbott Laboratories (U.S.)
10.2.2. Apotex Inc. (Canada)
10.2.3. AstraZeneca (U.K)
10.2.4. Dr. Reddy’s Laboratories Ltd. (India)
10.2.5. GlaxoSmithKline plc (U.K)
10.2.6. Mylan N.V. (U.S.)
10.2.7. Pfizer Inc. (U.S)
10.2.8. Novartis AG (Switzerland)
10.2.9. Sanofi (France)
10.2.10. Sun Pharmaceutical Industries Ltd. (India)
10.2.11. Teva Pharmaceutical Industries Ltd (Israel)
Valeant Pharmaceuticals International, Inc. (Canada)
